Feb 23 - Novo Nordisk’s stock tumbled by more than 15% on Monday after the company disclosed that its investigational obesity treatment, CagriSema, did not perform as well as Eli Lilly’s tirzepatide in a comparative clinical trial. The trial had been intended to demonstrate that CagriSema was at least as effective at producing weight loss as tirzepatide, but it did not meet that objective, Novo Nordisk said in a statement.
The sell-off erased the final gains the company had accrued since the launch of Wegovy and returned the share price to levels seen before Wegovy helped elevate the company’s market value. Novo Nordisk, which had been valued at more than $600 billion in 2024, has lost roughly $400 billion of that valuation, according to the company’s own disclosure in the statement. By mid-morning trading in Copenhagen, the stock was at its lowest point since June 2021, the month Wegovy was first introduced.
Market analysts reacted to the trial outcome as a material setback for Novo Nordisk’s competitive position in the expanding obesity treatment space. J.P. Morgan analysts characterized the trial miss as likely to dampen demand for CagriSema, constrain long-term sales expectations and hinder Novo Nordisk’s ability to regain market share in obesity treatments. In their comment, the analysts noted that while CagriSema might still constitute an additional treatment option, its inferiority to Zepbound makes it unlikely to help Novo retake share in the segment.
The trial result feeds into broader investor unease about growing competition within obesity therapeutics, where market demand increasingly favors products that deliver the largest weight-loss outcomes. On Monday, Novo Nordisk was among the weakest performers on the STOXX 600 index. Shares of Danish peer Zealand Pharma dropped 6.7% on the same session, while Eli Lilly’s shares rose by about 4% in U.S. premarket trading.
The market reaction highlights how quickly trial readouts can reshape expectations for individual programs and for company valuations in a sector where clinical efficacy directly drives demand. For Novo Nordisk, the immediate consequence was a substantial re-pricing of expectations for CagriSema and a reversal of much of the market gains that followed Wegovy’s commercial success.
Investors and sector observers will now be watching how Novo Nordisk responds to the trial results, how competitive dynamics evolve, and how market share trajectories are affected across obesity treatments where efficacy comparisons are paramount.